Russian Federation plans mass vaccination against coronavirus from October

  • Russian Federation plans mass vaccination against coronavirus from October

Russian Federation plans mass vaccination against coronavirus from October

NY:A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19.

J&J's vaccine uses a common cold virus known as adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the body, causing the body to mount an immune defense against the virus.

Stoffels said prior tests of this type of vaccine in other diseases found that a second shot significantly increases protection.

The Philippines plans to buy 40 million doses worth $400 million for 20 million people, around a fifth of the country's 107 million population, the country's Finance Secretary Carlos Dominguez said.

Vaccinated animals developed neutralizing antibodies against the virus.

Six weeks later, all of the animals were exposed to the SARS-CoV-2 virus.

Of the six animals that received the optimal vaccine candidate, Ad26.COV2.S, none showed the virus in their lungs, and only one animal showed low levels of virus in nasal swabs.

Mike Ryan, executive director at the World Health Organisation, said earlier this months that "there is a long way to go" before the world gets its first approved vaccine. A single-shot immunization has practical and logistical advantages over a two-shot regimen for global deployment and pandemic control.

The trial began at Rana Hospital and Trauma Centre, which is among the 12 institutes selected for clinical trials of the vaccine.

The Minister also said that another vaccine, developed by Vector, a Novosibirsk-based infectious diseases lab, is undergoing clinical trials. Kathryn E. Stephenson, assistant professor of medicine at HMS and associate member of the Ragon Institute, is the principal investigator for the trial at BIDMC, which is funded by Janssen Vaccines & Prevention.

"The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention to move into a Phase 3 trial in September".